Drug interactions
Etrasimod + Lomustine
Severity: Major
Etrasimod and Lomustine: major interaction.
Last updated Sources: US FDA label
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Etrasimod lowers circulating lymphocytes by sequestering them in lymphoid tissue, and lomustine is myelosuppressive and immunosuppressive. Together they may increase the risk of serious infection. Labeling advises against combining etrasimod with antineoplastic or immunosuppressive therapy because it has not been studied.
What this interaction means in plain words
Etrasimod and Lomustine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Etrasimod belongs to Gastrointestinal Tract; Lomustine belongs to Oncology.
Why it happens
Additive immunosuppression: S1P receptor modulation reducing lymphocyte counts plus cytotoxic bone marrow suppression.
What to do
Avoid concurrent use where possible and allow washout of etrasimod after stopping. If combined, monitor CBC with lymphocyte counts and watch for infection.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Etrasimod and Lomustine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
References
Other interactions of Lomustine
- Adenovirus types 4 and 7 live + Lomustine Contraindicated
- Bcg vaccine live + Lomustine Contraindicated
- Influenza virus vaccine quadrivalent intranasal + Lomustine Contraindicated
- Lomustine + Measles mumps and rubella vaccine Contraindicated
- Lomustine + Measles mumps and rubella vaccine live Contraindicated
- Lomustine + Measles mumps rubella and varicella vaccine live Contraindicated
Other interactions of Etrasimod
- Abatacept + Etrasimod Major
- Amiodarone + Etrasimod Major
- Anagrelide + Etrasimod Major
- Anakinra + Etrasimod Major
- Anti-thymocyte + Etrasimod Major
- Asenapine + Etrasimod Major
Frequently asked questions
Can I take Etrasimod with Lomustine?
MediHelp rates the interaction as major. Etrasimod and Lomustine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Etrasimod lowers circulating lymphocytes by sequestering them in lymphoid tissue, and lomustine is myelosuppressive and immunosuppressive. Together they may increase the risk of serious infection. Labeling advises against combining etrasimod with antineoplastic or immunosuppressive therapy because it has not been studied.
How serious is the interaction between Etrasimod and Lomustine?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use where possible and allow washout of etrasimod after stopping. If combined, monitor CBC with lymphocyte counts and watch for infection.
What other medicines interact with Lomustine?
MediHelp also lists interactions of Lomustine with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Influenza virus vaccine quadrivalent intranasal. The full list is on the Lomustine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
